Nasdaq:US$13.41 (-0.23) | HKEX:HK$21.00 (-0.15) | AIM:£2.22 (+0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors